GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lincoln Pharmaceuticals Ltd (BOM:531633) » Definitions » Beneish M-Score

Lincoln Pharmaceuticals (BOM:531633) Beneish M-Score : -2.10 (As of Mar. 24, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Lincoln Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.1 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Lincoln Pharmaceuticals's Beneish M-Score or its related term are showing as below:

BOM:531633' s Beneish M-Score Range Over the Past 10 Years
Min: -2.81   Med: -2.35   Max: -1.62
Current: -2.1

During the past 13 years, the highest Beneish M-Score of Lincoln Pharmaceuticals was -1.62. The lowest was -2.81. And the median was -2.35.


Lincoln Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Lincoln Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lincoln Pharmaceuticals Beneish M-Score Chart

Lincoln Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.81 -2.48 -2.53 -1.72 -2.10

Lincoln Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.10 - - -

Competitive Comparison of Lincoln Pharmaceuticals's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lincoln Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Lincoln Pharmaceuticals's Beneish M-Score falls into.



Lincoln Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Lincoln Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1178+0.528 * 1.0173+0.404 * 0.9106+0.892 * 1.1312+0.115 * 1.0146
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9609+4.679 * 0.042965-0.327 * 1.0729
=-2.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ₹2,055 Mil.
Revenue was ₹5,712 Mil.
Gross Profit was ₹2,912 Mil.
Total Current Assets was ₹4,467 Mil.
Total Assets was ₹7,003 Mil.
Property, Plant and Equipment(Net PPE) was ₹1,865 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹106 Mil.
Selling, General, & Admin. Expense(SGA) was ₹413 Mil.
Total Current Liabilities was ₹923 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Net Income was ₹933 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹632 Mil.
Total Receivables was ₹1,625 Mil.
Revenue was ₹5,050 Mil.
Gross Profit was ₹2,619 Mil.
Total Current Assets was ₹3,672 Mil.
Total Assets was ₹5,874 Mil.
Property, Plant and Equipment(Net PPE) was ₹1,585 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹92 Mil.
Selling, General, & Admin. Expense(SGA) was ₹379 Mil.
Total Current Liabilities was ₹721 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2054.589 / 5712.178) / (1624.835 / 5049.547)
=0.359686 / 0.321778
=1.1178

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2618.67 / 5049.547) / (2911.985 / 5712.178)
=0.518595 / 0.509785
=1.0173

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4467.402 + 1865.491) / 7002.904) / (1 - (3672.128 + 1584.849) / 5874.202)
=0.095676 / 0.105074
=0.9106

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5712.178 / 5049.547
=1.1312

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(91.661 / (91.661 + 1584.849)) / (106.247 / (106.247 + 1865.491))
=0.054674 / 0.053885
=1.0146

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(412.529 / 5712.178) / (379.495 / 5049.547)
=0.072219 / 0.075154
=0.9609

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 922.771) / 7002.904) / ((0 + 721.452) / 5874.202)
=0.13177 / 0.122817
=1.0729

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(933.049 - 0 - 632.172) / 7002.904
=0.042965

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Lincoln Pharmaceuticals has a M-score of -2.10 suggests that the company is unlikely to be a manipulator.


Lincoln Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Lincoln Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Lincoln Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.

Lincoln Pharmaceuticals Headlines

No Headlines